Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Last month, we talked about why investors may want to wait for better levels to enter into the CRSP stock. Since then, the stock has seen a correction of over 28%.

What To Expect From CRISPR Stock After A 14% Drop In 10 Days?

Proto Labs

These companies may represent the future, but their stocks are getting pummeled in the present.

2 Cathie Wood Stocks That Are 40% Off

Is CRISPR Therapeutics Stock Poised to Soar Nearly 30%?

Gene editing has the potential to revolutionize medicine. With CRISPR Therapeutics leading the way, CRSP stock should benefit.

CRISPR Therapeutics Stock Looks Like a Long-Term Biotech Winner

CRISPR Therapeutics AG's (CRSP) CEO Samarth Kulkarni Presents At 33rd Annual ROTH Conference (Transcript)

Teladoc

Tesla's great, but these Cathie Wood favorites have even better growth prospects.

2 Stocks Cathie Wood Loves That Should Be Bigger Winners Than Tesla

With possibly the worst of the novel coronavirus pandemic over, on the surface CRSP stock seems to be a worthwhile rebound pick. However, the technical outlook suggests otherwise.

CRISPR Therapeutics Is a Falling Knife You Don't Want to Catch

ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10 to 15 and May 17 to 21, 2021.

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting

Beam Therapeutics

bluebird bio

Editas Medicine

Intellia Therapeutics

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today appeared first on InvestorPlace.

Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today

Crispr Therapeutics AG's (CRSP) CEO Samarth Kulkarni Presents at Barclays Global Healthcare Conference 2017 (Transcript)

Crispr Therapeutics offers one of the next big technologies and today shares of CRSP stock afford investors access to growth at a discount. The post Why CRSP Stock Is a Less Dicey Risk Asset Today appeared first on InvestorPlace.

Why CRSP Stock Is a Less Dicey Risk Asset Today

Roku

Block

Tesla

Yields are on the rise and valuation-propelled tech is getting deflated.

Bulls & Bears Battle It Out In Big Tech

One analyst thinks the company's foundational gene-editing tools have far more potential than many realize.

Is CRISPR Stock Heading to $160 in 2021?

BioMarin Pharmaceutical

General Electric

Anthem

American Outdoor Brands

American Water Works

Charles Schwab

Wheaton Precious Metals

Yext

With the trading day about halfway over, the broad markets had managed to push higher on the day, despite dipping into the red earlier.

Anthem, BioMarin, CRISPR, GE and More Thursday Afternoon Analyst Calls

Churchill Capital Corp IV

Virgin Galactic

The companies with game-changing technology are often the best growth picks.

Why It's Time to Go All-In on These 3 Revolutionary Stocks

Fulgent Genetics

These stocks made investors a lot of money in 2020. Which one will be the better choice this year?

Better Buy: CRISPR vs. Fulgent Genetics

The Buzzing Gene-Editing Market Of Crispr Therapeutics

The gene editing sector remains red-hot as the promise to transform the way disease is treated. CRISPR Therapeutics seems primed to exploit the technology for outsized share gains.

CRISPR Therapeutics: Roadblock Ahead

Apple

DocuSign

Plug Power

Veeva Systems

Zoom Video

Overvalued stocks are easy to find using metrics which indicate a stock should trade for less. But these ones keep bucking their critics.

7 Overvalued Stocks Investors Just Don't Get Tired Of

A few months back we talked about why the rally in CRSP stock may continue given the positive developments around CTX001, an experimental gene therapy for people with sickle cell disease and transfusion-dependent beta thalassemia. CRSP stock extended its rally from levels of around $107.

Time To Book Profits In CRISPR Stock After A 5x Rally?

Pure Storage

Spotify

Investors have done great in ARKK, but buying these three ARK Innovation stocks with hedged strategies is today's smart money trade. The post 3 ARK Innovation Stocks to Buy Right Now appeared first on InvestorPlace.

3 ARK Innovation Stocks to Buy Right Now

We are glad to announce that we have added Catherine Wood (Trades, Portfolio)'s ARK Investment Management as one of our Premium Gurus.

Top 5 Holdings of Catherine Wood's ARK Investment

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y

- More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 -

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Abbott Labs

Want to play it safe in a volatile market? Go for these three top-notch healthcare picks.

3 Top Healthcare Stocks to Buy in February

News for CRISPR Therapeutics Stock (CRSP)